Tirzepatide is not purely a GLP-1 drug. It activates GLP-1 receptors, but it also activates a second gut hormone receptor called GIP, making it the first dual-agonist medication in its class. This distinction matters because the added GIP activity appears to be a major reason tirzepatide produces larger effects on blood sugar and body weight than GLP-1-only medications like semaglutide.
How Tirzepatide Differs From Pure GLP-1 Drugs
GLP-1 receptor agonists like semaglutide and liraglutide work by mimicking a single gut hormone, GLP-1, which helps regulate blood sugar and appetite. Tirzepatide mimics two gut hormones at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both hormones are naturally released after you eat, and both stimulate insulin production, but they do so through different receptors and pathways.
Tirzepatide’s affinity for the GIP receptor is equal to the body’s own GIP hormone. Its binding to the GLP-1 receptor is about fivefold weaker than natural GLP-1, but it compensates with a unique quirk: it activates the GLP-1 receptor in a way that causes less desensitization over time. In practical terms, the receptor doesn’t “tune out” the drug signal as quickly. This biased signaling, combined with strong GIP activation, is thought to explain why tirzepatide outperforms single-target GLP-1 drugs in clinical trials.
GIP receptor activation also improves insulin sensitivity through a mechanism that’s independent of weight loss, giving tirzepatide a metabolic advantage that pure GLP-1 drugs don’t have.
Weight Loss: Tirzepatide vs. Semaglutide
Head-to-head comparisons consistently favor tirzepatide. A systematic review and meta-analysis found that tirzepatide produced about 4.6% greater body weight reduction and roughly 4.76 kg (about 10.5 pounds) more absolute weight loss than semaglutide. People on tirzepatide were also more than twice as likely to reach the 15% or 20% weight loss thresholds that are associated with meaningful improvements in obesity-related health conditions.
In the SURMOUNT-1 trial, which studied tirzepatide specifically for weight management in people without diabetes, the results over 72 weeks were striking. The 5 mg dose produced an average 15% body weight reduction, the 10 mg dose reached 19.5%, and the highest dose of 15 mg achieved 20.9%. For context, a person weighing 220 pounds on the highest dose would lose roughly 46 pounds on average.
Blood Sugar Control
For people with type 2 diabetes, tirzepatide reduced HbA1c (a measure of average blood sugar over two to three months) significantly across all doses in the SURPASS trial program. The 5 mg dose lowered HbA1c by about 1.9 percentage points, while the 15 mg dose brought it down by roughly 2.6 percentage points over 40 to 52 weeks of treatment. These reductions are large enough that many participants reached normal or near-normal blood sugar levels.
FDA-Approved Uses
Tirzepatide is sold under two brand names for two different purposes. Mounjaro is approved for improving blood sugar control in adults and children aged 10 and older with type 2 diabetes. Zepbound is the same molecule approved for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. The medication itself is identical; the branding reflects the approved indication.
How It’s Taken
Tirzepatide is a once-weekly injection that you give yourself under the skin, typically in the abdomen, thigh, or upper arm. Everyone starts at 2.5 mg, which is a ramp-up dose designed to let your body adjust, not a treatment dose. After four weeks, you move to 5 mg. From there, your prescriber can increase the dose by 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg per week. The gradual escalation helps minimize side effects, particularly nausea.
Common Side Effects
Digestive issues are by far the most frequent complaint, and they’re similar to what people experience on pure GLP-1 drugs, just sometimes more pronounced at higher doses. In clinical trials, 30 to 40% of participants reported nausea, 20 to 25% had diarrhea, 15 to 18% experienced vomiting, and 12 to 15% dealt with constipation. These side effects tend to be worst during dose increases and generally improve over weeks as the body adapts. The slow titration schedule exists specifically to soften this adjustment period.
Safety Warnings
Tirzepatide carries a boxed warning (the FDA’s most serious label warning) about thyroid tumors. In rat studies, the drug caused thyroid C-cell tumors at doses comparable to what humans take. Whether this translates to a real risk in people is unknown, but as a precaution, tirzepatide is contraindicated if you or a close family member has a history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness. This same class of warning applies to all GLP-1 receptor agonists, not just tirzepatide.
People with a known serious allergy to tirzepatide or any of its inactive ingredients should also not take the medication, as severe allergic reactions including anaphylaxis have been reported.
Why the Classification Matters
You’ll often see tirzepatide grouped with “GLP-1 drugs” in casual conversation, and that’s not entirely wrong. It does activate the GLP-1 receptor, and it shares many of the same effects: reduced appetite, slower stomach emptying, improved blood sugar control. But calling it a GLP-1 agonist alone misses half the picture. The GIP component isn’t just along for the ride. It independently improves insulin sensitivity, and the combination of both pathways produces results that no single-target GLP-1 drug has matched in head-to-head trials. The more precise term is “dual GIP/GLP-1 receptor agonist,” and that dual action is the core reason tirzepatide stands apart in its class.